Antisera reactive with the Abelson murine leukemia virus (A-MuLV)-specified P120 (anti-AbT sera) were produced in C57L/J mice. Of many strains tested, only C57L/J reproducibly rejected syngeneic A-MuLV-induced tumor cells; after multiple immunizations their sera would immunoprecipitate both P120 and Moloney-MuLV (M-MuLV) proteins. Using labeled A-MuLV-induced nonproducer cells, only P120 could be detected by anti-AbT sera, suggesting that it may be the only A-MuLV-specified protein. Reactivity of anti-AbT sera with P120 was not blocked by M-MuLV virion proteins, implying that the sera recognize a portion of P120 that is not homologous to any M-MuLV product. Anti-AbT sera stained the surface of live, A-MuLV-transformed nonproducer cells in a two-stage immunofluorescence assay, and such staining was not blocked by M-MuLV protein. Also, intact A-MuLV-transformed cells absorbed much of the reactivity of certain anti-AbT sera for P120. Thus a portion of P120 appears to be exposed on the surface of transformed cells. P120 lacks detectable carbohydrate, is not affected by endoglycosidase H, and cannot be labeled by lactoperoxidase-catalyzed iodination. Thus P120 is an unusual surface protein.
Abelson murine leukemia virus (A-MuLV) is a defective, transforming retrovirus isolated from a corticosteroid-treated BALB/c mouse that had been inoculated with the replicationcompetent virus, Moloney MuLV (M-MuLV) (1). A-MuLV has unique biological and biochemical properties that distinguish it from its parent virus; Most importantly, A-MuLV transforms a different class of hematopoietic target cells from M-MuLV (9-11, 13, 17, 18, 21-23) , and A-MuLV is capable of transforming fibroblastic cells (19) . A-MuLV, like other defective, transforming retroviruses, requires a helper virus (like M-MuLV) to provide its structural proteins and its enzymatic functions for replication (5, 27) .
A-MuLV RNA is 5,600 bases long and shares sequence homology with M-MuLV at its 5' and 3' ends (A. Shields, Ph.D. thesis, Massachusetts Institute of Technology, Cambridge, 1979) . A single stretch of 3,600 nucleotides of sequence not derived from M-MuLV fills the center of the A-MuLV genome.
The only known protein encoded by the AMuLV genome is one of 120,000 molecular weight called P120 (14, 29) . This protein contains serological determinants of the M-MuLV amino-terminal gag gene products-p15, p12, and a portion of p30-fused to a region of approximately 90,000 molecular weight derived from the A-MuLV unique sequences.
In an attempt to make an antiserum that might recognize the unique (non-M-MuLV) determinants on the A-MuLV P120, we have used the one case we could find in which mice would reproducibly reject a syngeneic A-MuLV-transformed cell line. Because xenogeneic sera from animals that have rejected Rous sarcoma virusinduced tumors have been so useful in defining the transforming protein of that virus (3, 12), it seemed possible that syngeneic immunization with A-MuLV-induced tumors would be similarly useful. Risser et al. (16) have already shown the utility of this approach in their description of an A-MuLV-related cell surface antigen detected by antibody-mediated cytotoxity. We have prepared sera that precipitate P120 via its unique determinants and have used the sera in a two-stage immunofluorescence assay to detect an A-MuLV-specific cell surface antigen.
VOL. 31, 1979 cell line LI and subclone L1-2, nonproducer NIH mouse fibroblast line A2, and rat cell line Ab-NRK have been previously described (17, 29) .
Cell labeling and immunoprecipitation. All radioactive chemicals were purchased from New England Nuclear Corp., Boston Sepharose-coupled M-MuLV virion proteins. A 40-mg sample of unlabeled M-MuLV protein was derived from virions that were purified from culture supernatant fluids by two cycles of sucrose gradient centrifugation in the MIT Cell Culture Center. The virions were lysed with 5% Triton X-100-0.5 M NaCl, dialyzed to pH 8.5 (100 mM NaHCO3), and coupled with 4 g of freeze-dried CNBr-activated Sepharose 4B (Pharmacia Fine Chemical Corp.) ovemight at 4°C.
[3S]methionine-labeled M-MuLV (106 cpm) was added as a tracer. After washing, the final coupled protein was estimated at 2.5 mg/ml of swollen resin.
RESULTS
Production of an antiserum reactive with A-MuLV-specified P120 (anti-AbT). To develop a syngeneic regressor system for production of anti-A-MuLV sera, various cell line and mouse strain combinations were examined. The approach used involved injecting mice with live, in vitro-derived transformed lymphoid cells, monitoring the mice for tumor formation and subsequent rejection, and then challenging them with increasing cell doses. Activity against AMuLV-specified proteins was determined by direct immunoprecipitation (see below).
Initially, 15 independently derived A-MuLVtransformed lymphoid cell lines of BALB/c origin were injected into syngeneic mice. Progressive, disseminated tumors developed in the majority of the mice, a finding consistent with earlier reports (10, 17, 21) . Use of low doses (103 cells per mouse) of nonproducer cells given intraperitoneally resulted in 100% mortality in 3 weeks. When low doses of live or mitomycin Ctreated cells (injected subcutaneously) did not kill all of the animals, the survivors failed to reject increased doses of cells and did not produce a demonstrable response to A-MuLV proteins. BALB/c-derived H-2k congenic mice rejected high doses (>106 cells per mouse) of BALB/c-derived nonproducer cells but did not respond to A-MuLV proteins.
Because the BALB/c system proved unsuccessful, lymphoid cell lines derived from SWR/ J, C57BRcd/J, C57BL6/J, and C57L/J mice were examined. Groups of 20 mice were injected with two SWR/J and one C57BRcd/J-derived cell line, and all of the mice tested succumbed to the initial inoculum. (Fig. 1) . Animals numbered 1 to 12 were injected and boosted with cell line Li, and numbers 13 to 17 were injected with subclone Li-2. The presence of detectable antibody reactive to the M-MuLV core precursor (Pr6'5ga) and envelope precursor (Pr8Oen) varied but was more pronounced in the group injected with Li. During repeated cycles of immunization, these differences in precipitating antibody patterns were minimized and a common pattern of prominent response to P120 and Pr8Oenv and weak or absent response to Pr659'9 was found. Only antibody that could bind to the Staphylococcus aureus immune adsorbent was monitored in the above screenings, but subsequent testing of serum pools employing goat anti-mouse immunoglobulin in a two-stage precipitation assay did not reveal any additional specificities (data not To search for additional A-MuLV-specified proteins that might lack methionine, we labeled AMuLV-transformed cells with a variety of protein precursors, or by chemical iodination techniques, and used extracts of these labeled cells in direct immunoprecipitation assays with pools of anti-AbT serum. To simplify the analysis, we used A-MuLV-transformed, nonproducer cell lines, like 2M3, to direct attention to A-MuLV genome expression rather than that of the MMuLV helper virus. When 2M3 cells were pulselabeled (1 h) with [3H]leucine ( Fig. 2A) or 4C-mixed amino acids (Fig. 2C) , or labeled for 18 h with [3H]leucine (Fig. 2B) , the only reproducibly immunoprecipitable protein was the P120 protein. Similar tests were done using mouse and rat A-MuLV-transformed nonproducer fibroblast cultures with the same results.
To further evaluate the specificities of the anti-AbT serum, and to search for putative AMuLV-related proteins that could have extremely low synthetic rates but be stable enough to accumulate within the cells, we used chemical iodination techniques. Lactoperoxidase-catalyzed iodination labels available tyrosine and histidine residues on peripheral membrane proteins. It has been used to label the MuLV env gene product, gp7O, on the virion and cell surface (6, 30, 31) . A-MuLV-transformed nonproducer line 2M3 (Fig. 3, lane A) and its M-MuLV-superinfected derivative 2M3/M (Fig. 3, lane B) were labeled to high specific activity, and extracts were immunoprecipitated with anti-AbT serum. Only gp7O on the producer cell line 2M3/ M was detected. Neither P120 or other potential A-MuLV proteins were labeled.
We extended our studies to a reagent that could penetrate into cells and label proteins the Bolton-Hunter reagent. It reacts rapidly with free amino groups and will function at pH 7.5 and low temperature. Intact 2M3 (Fig. 3C ) and 2M3/M (Fig. 3D) (Fig. 2D) , the Pr8Oenv precursor was heavily labeled but P120 was not labeled. The faint band(s) at 90,000 to 95,000 molecular weight is the glycosylated form of the M-MuLV gag gene (gp9Ogag) similar to that described for other ecotropic MuLV strains (26 (Fig. 4A) or anti-AbT serum (Fig. 4B) Table 1 ).
Only the anti-AbT serum was able to stain the cell membrane of A-MuLV-transformed nonproducer lines such as 2M3 (Fig. 5) . Sera with specificity to the gag gene-related portion of P120, like anti-p15 and anti-p30, although able to precipitate P120 from lysed cells (29) sorbed serum was markedly reduced in its ability to stain the nonproducer cell line 2M3, which expresses only P120, but retained the ability to stain the M-MuLV-superinfected 2M3/M line, which also expresses at the cell membrane the M-MuLV env gene products gp7O and p15E. cA 1-ml sample of 1:10-diluted anti-AbT was mixed with 2 ml of wet packed Sepharose 2B coupled with lysed M-MuLV proteins (2.5 mg of final protein bound per ml of Sepharose) for 6 h at 4°C. The serum was recovered by centrifugation and reclarified before use.
of the precipitating activity for P120 was left in different pools (the residual P120 in lane 3, Fig.  6C , is not evident in the print but was detectable on the autoradiogram). Therefore, a variable portion of the antibody to P120 may be reactive with determinants that are not accessible at the cell surface, but the majority could be absorbed by live cells. Similar absorption experiments using M-MuLV-infected NIH/3T3 cells or MMuLV-infected Moloney sarcoma virus-transformed cells did not remove anti-P120 activity from the anti-AbT serum.
In separate experiments (data not shown), we found that P120 in intact cells was resistant to digestion with the proteases trypsin and chymotrypsin under conditions that previously were shown to remove peripheral proteins like gp7O (30) . Such protease treatment did not diminish the ability of anti-AbT serum to stain A-MuLVtransformed cells.
Thus, it is likely that P120, or perhaps a fraction of the P120 molecules, exposes a portion of its 90,000-molecular weight unique region above the cell membrane but that other regions of the molecule, including the gag gene-related amino terminus, are buried in or beneath the lipid bilayer and not accessible to antibody molecules. The external region is not, however, detectably labeled by lactoperoxidase-catalyzed iodination and is not as protease sensitive as a peripheral membrane protein like gp7O.
DISCUSSION
In the process of rejecting syngeneic tumors caused by A-MuLV-transformed cells, C57L/J mice make a humoral antibody response to the A-MuLV-specified P120 protein. No other AMuLV-specific protein is detected by such sera, and much of the antibody is directed to the AMuLV-specific region of P120. The serum detects cell surface antigen by live-cell staining in a two-stage immunofluorescence test. Because P120 is the only A-MuLV protein reactive with the serum, the results imply that at least part of the A-MuLV-specific region of P120 is exposed on the cell surface. The ability of intact cells to absorb much of the reactivity to P120 also argues that the protein is partly exposed on the cell surface.
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